Výsledky vyhledávání - "Maysa Tamara Silveira Vilbert"

Outcomes of non-treatment naive melanoma patients with central nervous system relapse

Autor: Diana Paola Arteaga, David Hogg, Maysa Tamara Silveira Vilbert Pereira, Samuel Saibil, Raviya Singh, Marcus O. Butler, Luke Mantle, Hadee Lone, Sofia Genta, Diana Gray, Thiago Pimentel Muniz, Anna Spreafico

Publikováno v: Journal of Clinical Oncology. 39:9557-9557

9557 Background: Melanoma has a high probability of central nervous system (CNS) spread. Although first line nivolumab and ipilimumab resulted in 56% response rate and 29.2 months median overall survival (OS) in patients with melanoma brain metastase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d5276fe0546c8c61de8cb68ee6bbf10
https://doi.org/10.1200/jco.2021.39.15_suppl.9557

Zobrazit plný text záznamu

Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients

Autor: Vinicius Fernando Calsavara, Bruno Cezar de Mendonça Uchôa, Marcelle Goldner Cesca, Aldo Lourenço Abbade Dettino, Poliana de Andrade, Thiago Bueno Oliveira, Marcelo Corassa, Natasha Carvalho Pandolfi, Maysa Tamara Silveira Vilbert, Ricardo Lima Coelho, José Augusto Rinck

Publikováno v: Journal of Clinical Oncology. 38:e17545-e17545

e17545 Background: Androgen receptor-targeted agents Abiraterone and Enzalutamide (Abi/Ez) prolonged overall survival in metastatic castration resistant prostate cancer (mCRPC). Patients with very-low serum testosterone levels seem to have less benef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c457eb7755d79cf3c596a0b0a8e8a7e7
https://doi.org/10.1200/jco.2020.38.15_suppl.e17545

Zobrazit plný text záznamu

A web app nomogram based on real-life patients: Guide decision in first-line treatment for metastatic castration-resistant prostate cancer (mCRPC)

Autor: José Augusto Rinck, Aldo Lourenço Abbade Dettino, Natasha Carvalho Pandolfi, Thiago Bueno Oliveira, Marcelo Corassa, Vinicius Fernando Calsavara, Maysa Tamara Silveira Vilbert, Bruno Cezar de Mendonça Uchôa, Ricardo Lima Coelho, Poliana de Andrade, Marcelle Goldner Cesca

Publikováno v: Journal of Clinical Oncology. 38:e17538-e17538

e17538 Background: mCRPC phenotype involves androgen-receptor signalling mechanisms that support the use of abiraterone/enzalutamide (Abi/Ez). These therapies improve overall survival (OS) and quality-of-life, with a favourable safety profile. There

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3157d9bae416914091c29fdd18435f0a
https://doi.org/10.1200/jco.2020.38.15_suppl.e17538

Zobrazit plný text záznamu

Biomarkers of prolonged time to treatment failure in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A real life patients-based nomogram and web app

Autor: Vinicius Fernando Calsavara, Marcelle Goldner Cesca, José Augusto Rinck, Natasha Carvalho Pandolfi, Aldo Lourenço Abbade Dettino, Ricardo Lima Coelho, Maysa Tamara Silveira Vilbert, Thiago Bueno Oliveira, Mariana Pinheiro Xerfan, Marcelo Corassa

Publikováno v: Journal of Clinical Oncology. 38:202-202

202 Background: Survival outcomes for metastatic castration resistant prostate cancer (mCRPC) patients (pts) have greatly improved following the approval of Docetaxel and abiraterone(Abi)/enzalutamide(Ez). However, it is not clear who is likely to be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da8e0b7f4370d41970c26136466e958f
https://doi.org/10.1200/jco.2020.38.6_suppl.202

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání